ExonHit Therapeutics Inc. Launches First Product in Alzheimer  
12/3/2009 10:06:36 AM

PARIS--(BUSINESS WIRE)--Regulatory News: ExonHit Therapeutics (Paris:ALEHT) is pleased to announce that AclarusDx™ Alzheimer’s test (formerly known as EHT Dx21), its blood-based test for the detection of Alzheimer’s disease (AD), is now available as a Research Use Only (RUO) product for pharmaceutical companies and leading academic centers conducting clinical trials in Alzheimer’s disease.